A183490 Stock Overview
Engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Enzychem Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,499.00 |
| 52 Week High | ₩2,220.00 |
| 52 Week Low | ₩1,047.00 |
| Beta | 1.44 |
| 1 Month Change | 16.20% |
| 3 Month Change | 2.25% |
| 1 Year Change | -16.63% |
| 3 Year Change | -81.32% |
| 5 Year Change | -86.41% |
| Change since IPO | -71.76% |
Recent News & Updates
Positive Sentiment Still Eludes Enzychem Lifesciences Corporation (KOSDAQ:183490) Following 25% Share Price Slump
Dec 09
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Recent updates
Positive Sentiment Still Eludes Enzychem Lifesciences Corporation (KOSDAQ:183490) Following 25% Share Price Slump
Dec 09Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns
Feb 17
Shareholder Returns
| A183490 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.7% | -2.3% | 0.3% |
| 1Y | -16.6% | 11.7% | -1.5% |
Return vs Industry: A183490 underperformed the KR Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: A183490 underperformed the KR Market which returned -1.5% over the past year.
Price Volatility
| A183490 volatility | |
|---|---|
| A183490 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A183490 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A183490's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 122 | Ki-Young Sohn | www.enzychem.com |
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.
Enzychem Lifesciences Corporation Fundamentals Summary
| A183490 fundamental statistics | |
|---|---|
| Market cap | ₩117.04b |
| Earnings (TTM) | -₩7.86b |
| Revenue (TTM) | ₩82.07b |
1.5x
P/S Ratio-15.2x
P/E RatioIs A183490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A183490 income statement (TTM) | |
|---|---|
| Revenue | ₩82.07b |
| Cost of Revenue | ₩76.91b |
| Gross Profit | ₩5.17b |
| Other Expenses | ₩13.02b |
| Earnings | -₩7.86b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -98.42 |
| Gross Margin | 6.30% |
| Net Profit Margin | -9.57% |
| Debt/Equity Ratio | 2.0% |
How did A183490 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:32 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enzychem Lifesciences Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Sang-Hun Lee | iM Securities |